Cargando…
HIV/AIDS Vaccines: 2018
Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I w...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282490/ https://www.ncbi.nlm.nih.gov/pubmed/30099743 http://dx.doi.org/10.1002/cpt.1208 |
_version_ | 1783379005065396224 |
---|---|
author | Robinson, Harriet L. |
author_facet | Robinson, Harriet L. |
author_sort | Robinson, Harriet L. |
collection | PubMed |
description | Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I wrote a review, HIV AIDS Vaccines: 2007. This review, HIV AIDS Vaccines: 2018, focuses on the progress in the past 11 years. I begin with key challenges for the development of an AIDS vaccine and the lessons learned from the six completed efficacy trials, only one of which has met with some success. |
format | Online Article Text |
id | pubmed-6282490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62824902018-12-10 HIV/AIDS Vaccines: 2018 Robinson, Harriet L. Clin Pharmacol Ther Reviews Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I wrote a review, HIV AIDS Vaccines: 2007. This review, HIV AIDS Vaccines: 2018, focuses on the progress in the past 11 years. I begin with key challenges for the development of an AIDS vaccine and the lessons learned from the six completed efficacy trials, only one of which has met with some success. John Wiley and Sons Inc. 2018-10-09 2018-12 /pmc/articles/PMC6282490/ /pubmed/30099743 http://dx.doi.org/10.1002/cpt.1208 Text en © 2018 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Robinson, Harriet L. HIV/AIDS Vaccines: 2018 |
title |
HIV/AIDS Vaccines: 2018 |
title_full |
HIV/AIDS Vaccines: 2018 |
title_fullStr |
HIV/AIDS Vaccines: 2018 |
title_full_unstemmed |
HIV/AIDS Vaccines: 2018 |
title_short |
HIV/AIDS Vaccines: 2018 |
title_sort | hiv/aids vaccines: 2018 |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282490/ https://www.ncbi.nlm.nih.gov/pubmed/30099743 http://dx.doi.org/10.1002/cpt.1208 |
work_keys_str_mv | AT robinsonharrietl hivaidsvaccines2018 |